

South Australian Neonatal Medication Guidelines

# SMOFlipid with vitamins

## SMOF20%, Soluvit N, Vitalipid N infant (Fresenius Kabi®)

© Department for Health and Wellbeing, Government of South Australia. All rights reserved.

**Note:**

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

## Synonyms

**SMOF** (20%) stands for **S**oya oil (6%), **M**edium chain triglycerides (6%), **O**live oil (5%), **F**ish oil (3%)

Final volume contains 17% fat providing 1.7kcal/mL. 1mL of fat emulsion is equivalent to 0.17g of fat

## Dose and Indications

**Supply of energy, essential fatty acids and omega-3 fatty acids as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contraindicated**

### Intravenous infusion

Commence at 1g/kg/day, and increase daily as tolerated up to 3g/kg/day.

Infusion should be run over 24hrs.

Should be given with parenteral nutrition.

**Table 1:** Guide for Dose & infusion rate

Dose (gram/kg/day)	Approximate infusion rate (mL/kg/hour)
1	0.25
2	0.5
3	0.75

# SMOFlipid with vitamins

## SMOF20%, SoluVit N, Vitalipid N infant (Fresenius Kabi®)

### Preparation and Administration

25ml syringes contain: SMOF lipid (18ml), SoluVit (1.4ml), Vitalipid (5.6ml)

**Used for infusion rate <1ml/hr**

50ml syringes contain: SMOF lipid (36ml), SoluVit (2.8ml), Vitalipid (11.2ml)

**Used for infusion rate ≥1ml/hr**

Store syringes in fridge.

Syringes are stable at room temperature for 24hours.

### Adverse Effects

#### Common

Hypertriglyceridemia, hyperglycaemia, hyperbilirubinemia, abnormal LFTs, hypersensitivity reactions

### Monitoring

- > Serum triglyceride should be measured at baseline. Levels may be considered 1-2 days after initiation or adjustment of lipid infusion, and then preformed weekly thereafter if required. More frequent monitoring may be warranted in patients at high risk of hyperlipidaemia.
- > Liver function test
- > Platelet count
- > Glucose

### Practice Points

- > ESPGHAN 2018 recommends regular triglyceride monitoring in patients receiving intravenous lipid emulsion, and more frequent monitoring in cases with marked risk for hyperlipidaemia (e.g. patient with high lipid or glucose dosage, sepsis, catabolism, extremely low birth weight infants).
- > ESPGHAN 2018 suggests a triglyceride concentration of 3mmol/L, taken *during infusion*, as the upper limit. Reduction of the dosage can be considered if concentrations exceed this.
- > Should be given with parenteral nutrition.
- > SMOFlipid® is compatible via Y-site with total parenteral nutrition, fentanyl, midazolam, morphine, dopamine.
- > Use with caution in patients with sepsis or hyperbilirubinaemia. Septic, acidotic and post-operative neonates will have lower requirements.
- > 14%SMOFlipid with vitamins may be required in neonates with lipid intolerance. It may be ordered on request only from Fresenius Kabi® with approximate 2 day turnaround time (speak with your pharmacist).



# SMOFlipid with vitamins

## SMOF20%, SoluVit N, Vitalipid N infant (Fresenius Kabi®)

### References

- > Lapillonne A, ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids, 2018, Clinical Nutrition

### Document Ownership & History

<b>Developed by:</b>	SA Maternal, Neonatal & Gynaecology Community of Practice
<b>Contact:</b>	<a href="mailto:Health.NeoMed@sa.gov.au">Health.NeoMed@sa.gov.au</a>
<b>Endorsed by:</b>	SA Health Safety and Quality Strategic Governance Committee
<b>Next review due:</b>	12/02/2024
<b>ISBN number:</b>	978-1-76083-058-8
<b>PDS reference:</b>	CG307
<b>Policy history:</b>	Is this a new policy (V1)? <b>Y</b> Does this policy amend or update an existing policy? <b>N</b> If so, which version? Does this policy replace another policy with a different title? <b>N</b> If so, which policy (title)?

Approval Date	Version	Who approved New/Revised Version	Reason for Change
12/02/2019	V1	SA Health Safety and Quality Strategic Governance Committee	Original SA Health Safety and Quality Strategic Governance Committee approved version

